S3a and b, respectively) showed a trend of lower safety concerns with BIC/FTC/TAF compared with active control group, whereas the analysis of treatment-related AE (Fig.
← all excerpts
Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV.
1
—
—